Chemical Compound Review:
Dextrowarfarin 2-hydroxy-3-[(1R)-3-oxo-1- phenyl...
Synonyms:
- Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. Wang, J.P., Unadkat, J.D., McNamara, S., O'Sullivan, T.A., Smith, A.L., Trager, W.F., Ramsey, B. Clin. Pharmacol. Ther. (1994)
- The warfarin-sulfinpyrazone interaction: stereochemical considerations. Toon, S., Low, L.K., Gibaldi, M., Trager, W.F., O'Reilly, R.A., Motley, C.H., Goulart, D.A. Clin. Pharmacol. Ther. (1986)
- Microbial transformations of warfarin: stereoselective reduction by Nocardia corallina and Arthrobacter species. Davis, P.J., Rizzo, J.D. Appl. Environ. Microbiol. (1982)
- A PK-PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy. Hamberg, A.K., Dahl, M.L., Barban, M., Scordo, M.G., Wadelius, M., Pengo, V., Padrini, R., Jonsson, E.N. Clin. Pharmacol. Ther. (2007)
- VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Obayashi, K., Nakamura, K., Kawana, J., Ogata, H., Hanada, K., Kurabayashi, M., Hasegawa, A., Yamamoto, K., Horiuchi, R. Clin. Pharmacol. Ther. (2006)
- Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Takahashi, H., Sato, T., Shimoyama, Y., Shioda, N., Shimizu, T., Kubo, S., Tamura, N., Tainaka, H., Yasumori, T., Echizen, H. Clin. Pharmacol. Ther. (1999)
- Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin. O'Reilly, R.A. Clin. Pharmacol. Ther. (1981)
- Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Yang, H.Y., Lee, Q.P., Rettie, A.E., Juchau, M.R. Mol. Pharmacol. (1994)
- Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Kamali, F., Khan, T.I., King, B.P., Frearson, R., Kesteven, P., Wood, P., Daly, A.K., Wynne, H. Clin. Pharmacol. Ther. (2004)
- Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Takahashi, H., Kashima, T., Nomizo, Y., Muramoto, N., Shimizu, T., Nasu, K., Kubota, T., Kimura, S., Echizen, H. Clin. Pharmacol. Ther. (1998)
- Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Awni, W.M., Hussein, Z., Granneman, G.R., Patterson, K.J., Dubé, L.M., Cavanaugh, J.H. Clinical pharmacokinetics. (1995)
- Phase II metabolism of warfarin in primary culture of adult rat hepatocytes. Jansing, R.L., Chao, E.S., Kaminsky, L.S. Mol. Pharmacol. (1992)
- Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Yamazaki, H., Shimada, T. Biochem. Pharmacol. (1997)
- Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Wienkers, L.C., Wurden, C.J., Storch, E., Kunze, K.L., Rettie, A.E., Trager, W.F. Drug Metab. Dispos. (1996)
- Preferential inducibility of CYP1A1 and CYP1A2 by TCDD: differential regulation in primary human hepatocytes versus transformed human cells. Zhang, Z.Y., Pelletier, R.D., Wong, Y.N., Sugawara, M., Zhao, N., Littlefield, B.A. Biochem. Biophys. Res. Commun. (2006)
- Ticrynafen-racemic warfarin interaction: hepatotoxic or stereoselective? O'Reilly, R.A. Clin. Pharmacol. Ther. (1982)
- Stereoselective metabolism of conformational analogues of warfarin by beta-naphthoflavone-inducible cytochrome P-450. Heimark, L.D., Trager, W.F. J. Med. Chem. (1985)
- Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Andersson, T., Hassan-Alin, M., Hasselgren, G., Röhss, K. Clinical pharmacokinetics. (2001)
- Effect of quinidine on the 10-hydroxylation of R-warfarin: species differences and clearance projection. Chen, Q., Tan, E., Strauss, J.R., Zhang, Z., Fenyk-Melody, J.E., Booth-Genthe, C., Rushmore, T.H., Stearns, R.A., Evans, D.C., Baillie, T.A., Tang, W. J. Pharmacol. Exp. Ther. (2004)
- Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Yamazaki, H., Shimada, T. Arch. Biochem. Biophys. (1997)
- In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4'- and 10-hydroxywarfarin. Ngui, J.S., Chen, Q., Shou, M., Wang, R.W., Stearns, R.A., Baillie, T.A., Tang, W. Drug Metab. Dispos. (2001)
- Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. Osman, A., Enström, C., Arbring, K., Söderkvist, P., Lindahl, T.L. J. Thromb. Haemost. (2006)
- Development of the hepatic mixed-function oxidase system and its metabolism of warfarin in the perinatal rat. MacDonald, M.G., Fasco, M.J., Kaminsky, L.S. Developmental pharmacology and therapeutics. (1981)
- Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Scordo, M.G., Pengo, V., Spina, E., Dahl, M.L., Gusella, M., Padrini, R. Clin. Pharmacol. Ther. (2002)
- Kinetic study of cytochrome P450 3A4 activity on warfarin by capillary electrophoresis with fluorescence detection. Zhang, J., Ha, P.T., Lou, Y., Hoogmartens, J., Van Schepdael, A. Journal of chromatography. A. (2005)
- Plasma pharmacokinetics of warfarin enantiomers in cats. Smith, S.A., Kraft, S.L., Lewis, D.C., Freeman, L.C. J. Vet. Pharmacol. Ther. (2000)